person · Reporting owner

Agoglia Hoeltzel Mary T

Disclosed activity across 2 companies

Tapewire entity: 90978
SEC CIK: 0001467807

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	SVP Tax & Chief Acct. Officer	May 14, 2024	May 16, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date May 14, 2024 · Filed May 16, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	8,540.738	Reported balance After 2024-05-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-05-14 · Exercise / conversion · Acquired 5,946 · Balance 8,540.738 F1: Balance includes 8.414 shares of common stock received from her participation in a dividend reinvestment plan.
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	2,594.738	Reported balance After 2024-05-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-05-14 · Sale · Disposed 5,946 · Balance 2,594.738 F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $348.68 to $349.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	0	Reported balance After 2024-05-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-14 · Exercise / conversion · Disposed 5,946 · Balance 0 F3: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Balance includes 8.414 shares of common stock received from her participation in a dividend reinvestment plan.

F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $348.68 to $349.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F3: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 3,635 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Common Stock, $.25 Par ValueSEC Table I · non-derivative	IndirectBy 401 (k)	Reported balance After 2018-12-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 502.142 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.73 · Expires 2023-03-05	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 7,044 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 9,367 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 5,946 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 5,371 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-20 · Disposition to issuer · Disposed 5,035 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-20 · Disposition to issuer · Disposed 3,693 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)

F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: This option was fully vested and exercisable at the time of the Merger.

F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2024 Filed May 16, 2024 21:22 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	5,946	$0.00 Strike: $120.90	$0.00	Disclosure SEC source: 0001225208-24-006109 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 5,946 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 14, 2024 Filed May 16, 2024 21:22 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	5,946	$348.71	$2,073,449.28	Disclosure SEC source: 0001225208-24-006109 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,594.738 F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $348.68 to $349.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 14, 2024 Filed May 16, 2024 21:22 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	5,946	$120.90	$718,841.67	Disclosure SEC source: 0001225208-24-006109 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,540.738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Balance includes 8.414 shares of common stock received from her participation in a dividend reinvestment plan. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	532	$333.36	$177,347.52	Disclosure SEC source: 0001225208-24-003704 · doc4.xml · nonDerivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,586.324 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	224	$333.36	$74,672.64	Disclosure SEC source: 0001225208-24-003704 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,118.324 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:43 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,240	$0.00	$0.00	Disclosure SEC source: 0001225208-24-003704 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,342.324 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2021-2023 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 07, 2024 Filed Feb 9, 2024 22:04 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,867	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-24-001831 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 4,867 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
February 07, 2024 Filed Feb 9, 2024 22:04 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,867	$330.48	$1,608,446.16	Disclosure SEC source: 0001225208-24-001831 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,102.324 Read SEC document
February 07, 2024 Filed Feb 9, 2024 22:04 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	4,867	$78.04	$379,796.35	Disclosure SEC source: 0001225208-24-001831 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,969.324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Balance includes 9.444 shares of common stock received from her participation in a dividend reinvestment plan. Read SEC document
August 08, 2023 Filed Aug 10, 2023 21:07 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-23-008184 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,867 Underlying: Common Stock, $.01 Par Value · 4,500 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 08, 2023 Filed Aug 10, 2023 21:07 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	12,250	$291.00	$3,564,750.00	Disclosure SEC source: 0001225208-23-008184 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,092.88 Read SEC document
August 08, 2023 Filed Aug 10, 2023 21:07 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	4,500	$78.04	$351,157.50	Disclosure SEC source: 0001225208-23-008184 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,342.88 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Balance includes 40.134 shares of common stock received from her participation in a dividend reinvestment plan. Read SEC document
May 22, 2023 Filed May 24, 2023 20:09 UTC	Cigna Group CI · Entity 550	OtherCommon Stock, $.01 Par Value	503.6533	$254.89	$128,373.67	Disclosure SEC source: 0001225208-23-006198 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By 401(k) Disclosed balance after: 0 F1 · shares: Includes 2.2047 shares acquired through ongoing participation in The Cigna Group's 401(k) plan. Read SEC document
March 01, 2023 Filed Mar 3, 2023 22:11 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	106	$289.44	$30,680.64	Disclosure SEC source: 0001225208-23-003378 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,763.593 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	376	$294.27	$110,645.52	Disclosure SEC source: 0001225208-23-002990 · doc4.xml · nonDerivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,869.593 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	72	$294.27	$21,187.44	Disclosure SEC source: 0001225208-23-002990 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,245.593 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 24, 2023 Filed Feb 28, 2023 23:01 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,341	$0.00	$0.00	Disclosure SEC source: 0001225208-23-002990 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,317.593 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2020-2022 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 22, 2023 Filed Feb 25, 2023 02:11 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	1,568	$0.00 Strike: $294.61	$0.00	Disclosure SEC source: 0001225208-23-002819 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,568 Underlying: Common Stock, $.01 Par Value · 1,568 shares Expires 2033-02-22 F4 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2024. Read SEC document
February 22, 2023 Filed Feb 25, 2023 02:11 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	425	$0.00	$0.00	Disclosure SEC source: 0001225208-23-002819 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,976.593 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2024. F2 · balance_after: Balance includes 53.598 shares received from her participation in a dividend reinvestment plan. Read SEC document
August 09, 2022 Filed Aug 11, 2022 22:05 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,044	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-22-009439 · doc4.xml · derivative · entry 4 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 7,044 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 09, 2022 Filed Aug 11, 2022 22:05 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	7,044	$286.89	$2,020,860.20	Disclosure SEC source: 0001225208-22-009439 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,497.995 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $286.84 to $286.965 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 09, 2022 Filed Aug 11, 2022 22:05 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,044	$58.73	$413,694.12	Disclosure SEC source: 0001225208-22-009439 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,541.995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2022 Filed Mar 3, 2022 22:28 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	61	$236.48	$14,425.28	Disclosure SEC source: 0001225208-22-004167 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,432.024 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 25, 2022 Filed Mar 2, 2022 01:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	215	$229.64	$49,372.60	Disclosure SEC source: 0001225208-22-003746 · doc4.xml · nonDerivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,493.024 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 25, 2022 Filed Mar 2, 2022 01:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	154	$229.64	$35,364.56	Disclosure SEC source: 0001225208-22-003746 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,708.024 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 25, 2022 Filed Mar 2, 2022 01:18 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	695	$0.00	$0.00	Disclosure SEC source: 0001225208-22-003746 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,862.024 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2019-2021 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 23, 2022 Filed Feb 26, 2022 01:48 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	2,470	$0.00 Strike: $227.02	$0.00	Disclosure SEC source: 0001225208-22-003481 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 Underlying: Common Stock, $.01 Par Value · 2,470 shares Expires 2032-02-23 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2023. Read SEC document
February 23, 2022 Filed Feb 26, 2022 01:48 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	551	$0.00	$0.00	Disclosure SEC source: 0001225208-22-003481 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,167.024 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2023. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	372	$210.31	$78,235.32	Disclosure SEC source: 0001225208-21-004360 · doc4.xml · nonDerivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,503 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	151	$210.31	$31,756.81	Disclosure SEC source: 0001225208-21-004360 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2021 Filed Mar 3, 2021 01:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,201	$0.00	$0.00	Disclosure SEC source: 0001225208-21-004360 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:23 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	2,789	$0.00 Strike: $213.80	$0.00	Disclosure SEC source: 0001225208-21-003981 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,789 Underlying: Common Stock, $.01 Par Value · 2,789 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document
February 24, 2021 Filed Feb 27, 2021 01:23 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	585	$0.00	$0.00	Disclosure SEC source: 0001225208-21-003981 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	554	$179.41	$99,393.14	Disclosure SEC source: 0001225208-20-003952 · doc4.xml · nonDerivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,240 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,781	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003952 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,794 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	83	$185.76	$15,418.08	Disclosure SEC source: 0001225208-20-003952 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,013 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	2,383	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001225208-20-003817 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,383 Underlying: Common Stock, $.01 Par Value · 2,383 shares Expires 2030-02-26 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	651	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003817 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document
November 20, 2019 Filed Nov 21, 2019 22:52 UTC	Cigna Group CI · Entity 550	GiftCommon Stock, $.01 Par Value	1,000	$0.00	$0.00	Disclosure SEC source: 0001225208-19-014750 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,445 Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:24 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	529	$177.85	$94,082.65	Disclosure SEC source: 0001225208-19-004746 · doc4.xml · nonDerivative · entry 2 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,445 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:24 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,657	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004746 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:21 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	2,354	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-19-004237 · doc4.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354 Underlying: Common Stock, $.01 Par Value · 2,354 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:21 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	682	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004237 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · SVP Tax & Chief Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,317 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document
February 15, 2019 Filed Feb 20, 2019 23:01 UTC	Cigna Group CI · Entity 550	OtherCommon Stock, $.01 Par Value	17.3026	$196.17	$3,394.20	Disclosure SEC source: 0001225208-19-003123 · doc4.xml · nonDerivative · entry 1 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 484.7613 F1 · balance_after: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	3,693	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 8 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 3,693 shares Expires 2028-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,035	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 7 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,035 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,371	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 6 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,371 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,946	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 5 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,946 shares Expires 2025-02-25 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	9,367	Not disclosed Strike: $78.04	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 4 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 9,367 shares Expires 2024-02-26 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:39 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	7,044	Not disclosed Strike: $58.73	Not disclosed	Disclosure SEC source: 0001567619-18-008647 · doc1.xml · derivative · entry 3 Agoglia Hoeltzel Mary T · CIK 0001467807 · VP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 7,044 shares Expires 2023-03-05 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.